Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1006)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 September 2024
Diabetic retinopathy: management and monitoring (NG242)Product type:GuidanceProgramme:NICE guidelinePublished: 13 August 2024
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (IPG787)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 16 May 2024
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 March 2024
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 December 2023
Ranibizumab for treating diabetic macular oedema (TA274)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2023Published: 27 February 2013
Tirzepatide for treating type 2 diabetes (TA924)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 October 2023
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)Product type:GuidanceProgramme:NICE guidelineLast updated: 11 May 2023Published: 1 August 2015
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2023
Neuropad for detecting preclinical diabetic peripheral neuropathy (MTG38)Product type:GuidanceProgramme:Medical technologies guidanceLast updated: 21 September 2022Published: 10 September 2018
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 September 2022
Brolucizumab for treating diabetic macular oedema (TA820)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 August 2022
Type 1 diabetes in adults: diagnosis and management (NG17)Product type:GuidanceProgramme:NICE guidelineLast updated: 17 August 2022Published: 26 August 2015
Faricimab for treating diabetic macular oedema (TA799)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Type 2 diabetes in adults: management (NG28)Product type:GuidanceProgramme:NICE guidelineLast updated: 29 June 2022Published: 2 December 2015
3C Patch for treating diabetic foot ulcers (MTG66)Product type:GuidanceProgramme:Medical technologies guidancePublished: 7 March 2022
Diabetes in pregnancy: management from preconception to the postnatal period (NG3)Product type:GuidanceProgramme:NICE guidelineLast updated: 16 December 2020Published: 25 February 2015
Ranibizumab for treating diabetic retinopathy (terminated appraisal) (TA637)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 June 2020
Sotagliflozin with insulin for treating type 1 diabetes (TA622)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 February 2020
Diabetic foot problems: prevention and management (NG19)Product type:GuidanceProgramme:NICE guidelineLast updated: 11 October 2019Published: 26 August 2015
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 June 2019
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2019
The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)Product type:GuidanceProgramme:Medical technologies guidanceLast updated: 25 March 2019Published: 25 March 2014
Type 2 diabetes: prevention in people at high risk (PH38)Product type:GuidanceProgramme:Public health guidelineLast updated: 15 September 2017Published: 12 July 2012
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 23 November 2016Published: 26 June 2013
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 November 2016
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 May 2016
Aflibercept for treating diabetic macular oedema (TA346)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2015
Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (IPG518)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 March 2015
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2015
VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)Product type:GuidanceProgramme:Medical technologies guidanceLast updated: 1 March 2015Published: 31 December 2014
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2014
Type 2 diabetes prevention: population and community-level interventions (PH35)Product type:GuidanceProgramme:Public health guidelinePublished: 10 May 2011
Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 September 2008
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2008
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (IPG257)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 April 2008
PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes (MIB312)Product type:AdviceProgramme:Medtech innovation briefingPublished: 13 December 2022
d-Nav insulin management app for type 2 diabetes (MIB285)Product type:AdviceProgramme:Medtech innovation briefingPublished: 8 February 2022
AI technologies for detecting diabetic retinopathy (MIB265)Product type:AdviceProgramme:Medtech innovation briefingPublished: 6 July 2021
Dexcom G6 for real-time continuous glucose monitoring (MIB233)Product type:AdviceProgramme:Medtech innovation briefingPublished: 3 November 2020
t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes (MIB227)Product type:AdviceProgramme:Medtech innovation briefingPublished: 22 September 2020
Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)Product type:AdviceProgramme:Medtech innovation briefingPublished: 24 April 2018
FreeStyle Libre for glucose monitoring (MIB110)Product type:AdviceProgramme:Medtech innovation briefingLast updated: 29 September 2017Published: 3 July 2017
Aptiva for painful diabetic neuropathy (MIB119)Product type:AdviceProgramme:Medtech innovation briefingPublished: 13 September 2017
MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes (MIB51)Product type:AdviceProgramme:Medtech innovation briefingPublished: 12 February 2016
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)Product type:AdviceProgramme:Evidence summaryPublished: 2 December 2015
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)Product type:AdviceProgramme:Evidence summaryPublished: 2 December 2015
Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)Product type:AdviceProgramme:Evidence summaryPublished: 3 July 2015
Type 2 diabetes: insulin degludec (ESNM25)Product type:AdviceProgramme:Evidence summaryPublished: 10 September 2013
Diabetes in pregnancy (QS109)Product type:Quality standardLast updated: 10 January 2023Published: 19 January 2016
Diabetes in children and young people (QS125)Product type:Quality standardLast updated: 31 March 2022Published: 14 July 2016
Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)Product type:Quality standardPublished: 11 May 2018
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 July 2025
Type 2 diabetes in adults: management (medicines update)Status:In developmentProgramme:NICE guidelineExpected publication date: 30 July 2025
Diabetic retinopathy - ruboxistaurin [ID382]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating type 2 diabetes [ID1450]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dulaglutide for treating type 2 diabetes [ID1451]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sotagliflozin for treating type 2 diabetes [ID1657]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Insulin icodec for treating type 2 diabetes [ID6175]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Aflibercept for untreated diabetic macular oedema [TSID10621]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Cardiometabolic disease prevention and treatment guidelinesStatus:In developmentProgramme:NICE HubExpected publication date: TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
AI in retinal scanning MT524 (MIB265)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes, (MT740)Status:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Insulin efsitora alfa for treating type 2 diabetes in people on daily insulin injections [ID6499]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [TSID12131]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Orforglipron for treating type 2 diabetes [TSID12130]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC